Reckitt (LSE: RKT) edges up 0.11% near 52-week lows as Mead Johnson sale drags on the Kris Licht restructuring story

Reckitt (LSE: RKT) shares close up 0.11% at 4,551p on Friday, May 15, 2026, in a tightly bounded move that leaves the stock just above its 52-week low of 4,518p, marking one of the weakest periods in the Slough-headquartered consumer health and hygiene group’s recent history. The shares have lost more than 25% from levels above 6,000p just five months ago in January 2026, even as chief executive Kris Licht has executed the Essential Home divestment, run the £1 billion share buyback toward two-thirds completion, and reaffirmed Core Reckitt full-year guidance of 4% to 5% like-for-like net revenue growth. The persistent share price weakness reflects three overlapping pressures: the still-unresolved Mead Johnson Nutrition sale process, the H1 2026 margin compression of approximately 200 basis points versus H1 2025, and the broader consumer staples rotation away from defensive holdings during a year dominated by AI and energy themes. The next major catalyst for shareholders is the H1 2026 interim results on July 29, where Licht will need to demonstrate that the H2 margin recovery is materialising and that the Mead Johnson sale process is reaching a definitive conclusion.

What does Reckitt actually do today, and how does the post-Essential Home Reckitt differ from the conglomerate of two years ago?

Reckitt is a British multinational consumer goods company headquartered in Slough, United Kingdom, employing approximately 36,200 people across 60 countries and selling products in more than 200 markets. Formed in 1999 from the merger of British company Reckitt and Colman and Dutch company Benckiser, the group rebranded under the simpler Reckitt corporate name in 2021. The current portfolio is structured around three reporting categories. Core Reckitt comprises the high-growth Powerbrands across hygiene, health and nutrition, including Dettol, Lysol, Mucinex, Strepsils, Gaviscon, Durex, Veet, Finish, Vanish, Harpic, Cillit Bang, Air Wick, Clearasil, Disprin and Calgon. Mead Johnson Nutrition operates as a non-core infant formula business pending divestiture, anchored by the Enfamil and Nutramigen brands. The recently divested Essential Home portfolio of household cleaning brands, sold for approximately $5 billion at the end of 2025, continues to generate transitional services income and 30% associate income through Reckitt’s retained minority stake.

For 2025, Core Reckitt delivered like-for-like net revenue growth of 5.2%, ahead of the 4% to 5% medium-term guidance range, with Emerging Markets growing 14.6% on a like-for-like basis and double-digit growth in China, India, Indonesia and Colombia. The full-year results released on March 5, 2026 demonstrated that the underlying portfolio strategy is delivering, but the share price has not reflected that operational performance. Group adjusted operating margin in 2025 reached 24.6% in H1 and stabilised at strong levels for the full year, providing the baseline against which 2026 H1 margin compression is being measured.

The risk profile of the post-Essential Home Reckitt sits at the intersection of three structural pressures. First, the continued overhang of the Mead Johnson Nutrition sale, where the US infant formula litigation has complicated buyer interest and extended the timeline well beyond Kris Licht’s original 2024 announcement of intention to divest. Second, the stranded costs associated with the Essential Home divestment, which the Fuel for Growth productivity programme is designed to absorb but which create H1 2026 margin headwinds before the H2 recovery. Third, the broader consumer staples sector environment, where defensive consumer health names have lagged the FTSE 100 as investor focus rotates toward AI, energy and financial sector themes.

How does the April 22 Q1 trading update set up the rest of the 2026 reporting calendar?

The Q1 2026 trading update on April 22 reported a mixed quarter with clear structural drivers. Core Reckitt delivered like-for-like net revenue growth of 1.3%, well below the 4% to 5% full-year target, but stripping out the seasonal over-the-counter brands hit by a weak cold and flu season the growth improves to 3.1%. Mead Johnson Nutrition declined 2.7% on a like-for-like basis to £531 million, with volume down 6.8% offset by price and mix up 4.1%, reflecting tough comparables after the inventory rebuild in North America in Q1 2025. Group net revenue of £3,247 million was down 2.2% on a like-for-like basis when including Mead Johnson, with reported revenue down 11.8% reflecting the disposal of Essential Home and foreign exchange headwinds.

The geographic mix told the clearer story. Emerging Markets delivered 7.6% like-for-like growth to £1,087 million, powered by Dettol, Gaviscon and the vitamins, minerals and supplements portfolio, with double-digit growth in China and India continuing the multi-quarter trend. North America declined 0.9% on a like-for-like basis due to retailer destocking and the weaker cold and flu season impact on Mucinex and other seasonal OTC brands. Europe fell 4.2% on a like-for-like basis, reflecting a challenging trading environment with no expected catalysts for recovery and continued private label competition.

Management reaffirmed the full-year guidance of 4% to 5% like-for-like net revenue growth for Core Reckitt, citing the expected reset to a more normal cold and flu season in H2, the stepped-up innovation pipeline including Mucinex 12 Hour Cold and Fever shipping in June in North America, improving execution in Europe, and sustained strength in China and India. The full-year Group adjusted operating profit margin guidance was maintained, with delivery weighted to H2 and H1 expected to be approximately 200 basis points below H1 2025’s 24.6%.

The execution risk on the H2 acceleration is meaningful. The dependence on cold and flu season normalisation is the single largest assumption, with two consecutive weak seasons having compressed the seasonal OTC business. The Iran war commodity inflation is putting additional pressure on input costs, while the stranded costs from the Essential Home divestment are running at roughly the rate that the Fuel for Growth programme can offset. Any miss against the H2 acceleration would trigger investor concern about whether the structural turnaround thesis remains intact.

Why is the Mead Johnson Nutrition sale process taking so long, and what does it mean for the share price?

Kris Licht announced Reckitt’s intention to divest Mead Johnson Nutrition in 2024, describing the business as a very good business but flagging that complex litigation had created uncertainty. Nearly two years later, no formal buyer has been announced. The most recent reports point to Danone as the most likely strategic acquirer, with the French food group hosting active discussions but no concluded transaction. Other reported interest from private equity buyers has been more episodic.

The complication is the US infant formula litigation exposure that comes attached to any Mead Johnson sale. Lawsuits relating to necrotising enterocolitis allegations and other product liability claims have been progressing through US courts, with cumulative legal provisions and settlement potential creating uncertainty about the final net cash proceeds from any sale. The legal liabilities can be structured in various ways through a sale process, but each structure carries different risk-sharing implications between Reckitt and the eventual buyer.

The implications for Reckitt shareholders are threefold. First, the longer the sale process extends, the longer the dilutive effect of holding a non-core asset weighs on group margins and capital allocation flexibility. Second, the litigation overhang creates uncertainty about the final monetary value of any transaction, with potential outcomes ranging from a clean cash sale at a meaningful valuation to a more complex structured deal with retained contingent liabilities. Third, the continued speculation about which buyer will emerge and at what price creates persistent share price volatility that compounds the broader consumer staples sector weakness.

The share price weakness over the past five months partly reflects the Mead Johnson uncertainty. The shares hit a nine-month low in April 2026 as Mead Johnson acquisition rumours intensified without resolution, with Barclays cutting price targets and other analysts moderating expectations. Even with the rumoured Danone interest, a definitive announcement could either lift sentiment substantially if the price and structure exceed expectations, or further pressure the shares if the terms reveal more substantial liability retention than the market has priced.

What does the Essential Home divestment outcome tell investors about the broader restructuring strategy?

The Essential Home portfolio sale closed at the end of 2025 at an enterprise value of approximately $5 billion, with the buyer being a private equity consortium. Reckitt retained a 30% associate stake, which provides continued exposure to the divested business’s performance through equity-accounted earnings, plus approximately £25 million of pre-tax income from transitional services agreements during 2026. The total cash proceeds from the disposal supported the £1 billion share buyback programme that has been running through 2026, with £669 million completed by April 17, 2026.

The strategic logic for divesting Essential Home was clear. The household cleaning portfolio, including brands such as Air Wick, Calgon, Cillit Bang and Harpic, operated in slower-growth, lower-margin categories than the Powerbrands within Core Reckitt. By removing these brands from the consolidated portfolio, Reckitt could focus capital allocation, marketing investment and management attention on the higher-growth health and hygiene Powerbrands. The 30% associate stake retains exposure to any value uplift from the private equity owner’s value creation plan, while the cash proceeds enable shareholder returns and the strategic flexibility to pursue further portfolio actions.

The execution complication is the stranded costs. When a business segment is divested but the corporate centre remains, certain costs that were previously allocated across all segments are now borne by the remaining business. For Reckitt, these stranded costs are estimated to be material enough to compress group margins by approximately 200 basis points in H1 2026 versus H1 2025, before the Fuel for Growth productivity programme delivers offsetting savings through H2. The market is treating this as a transitional pressure rather than a structural problem, but the H1 margin compression is one of the factors weighing on the share price.

How does the broader Iran war commodity cost environment affect Reckitt’s H2 margin recovery?

The Iran war that began on February 28, 2026 has driven commodity prices higher across multiple inputs that affect Reckitt’s cost base. Crude oil derivatives feed into surfactants, fragrance compounds, plastic packaging and lubricants. Energy costs affect manufacturing, distribution and refrigeration. Freight rates have risen as global shipping reroutes around Middle East security risks. For a consumer goods company with manufacturing operations across Europe, Asia and the Americas, the cumulative cost impact is material.

Reckitt’s response combines three levers. First, pricing increases that flow through to consumers, particularly in emerging markets where the volume-led growth model has supported sustained 7.6% like-for-like growth despite higher prices. Second, the Fuel for Growth productivity programme that delivered savings sufficient to offset the stranded costs from Essential Home and is now being scaled to address additional commodity inflation. Third, mix management through innovation launches in premium segments and category extensions that command higher prices per unit.

The execution risk is that the H2 margin recovery depends on the cumulative impact of these levers exceeding the continued commodity inflation. If Iran war tensions escalate further, oil prices could re-test the early-2026 peaks above $130 per barrel, compressing margins beyond what pricing and productivity can offset. Conversely, if US-Iran peace talks deliver progress and oil prices revert toward the $80 to $90 range, the H2 margin trajectory could exceed expectations, providing earnings upside that would catalyse the share price recovery.

How is the market currently pricing Reckitt against analyst consensus and the implied scenarios?

Reckitt shares trade at 4,551p, with a market capitalisation of approximately £30 billion. The dividend yield at current prices is approximately 4.4%, reflecting the persistent share price weakness rather than any dividend increase. The trailing twelve-month price-to-earnings ratio is approximately 11 times, below the consumer staples sector average and meaningfully below the historical 5-year average of around 17 times. The consensus 12-month analyst price target stands at 6,229p, implying approximately 37% upside from current levels, with 13 analysts rating the stock Buy and zero rating it Sell.

The analyst rating dispersion is unusual for a stock trading near 52-week lows. The bull case anchors on four pillars. First, Core Reckitt’s 5.2% full-year 2025 like-for-like growth and consistent emerging markets momentum demonstrate that the underlying portfolio strategy works. Second, the Powerbrands across hygiene and health hold number-one or number-two positions globally, providing pricing power and category defensibility. Third, the £1 billion buyback running through 2026 effectively retires share count at a discount, creating mechanical earnings per share accretion. Fourth, the H2 margin recovery thesis combined with potential Mead Johnson sale resolution offers binary upside catalysts within the next 12 months.

The bear case rests on three concerns. First, the prolonged Mead Johnson sale process is creating valuation uncertainty that may not resolve cleanly. Second, the H1 2026 margin compression is more severe than initially expected, raising questions about whether Fuel for Growth can fully offset stranded costs and commodity inflation. Third, the broader consumer staples sector environment, with the Magnum demerger valuation disappointment, GLP-1 demand concerns and the Trump administration’s Make America Healthy Again campaign all creating sector-wide headwinds.

What does the Mucinex 12 Hour Cold and Fever launch and broader innovation pipeline tell investors?

Reckitt’s H2 acceleration thesis depends substantially on innovation launches across the Powerbrand portfolio. The most prominent near-term launch is Mucinex 12 Hour Cold and Fever, shipping in June 2026 in North America, which extends the Mucinex franchise into the high-growth multi-symptom category and addresses a longstanding consumer demand for longer-acting relief. Mucinex is the leading cold and flu brand in the US over-the-counter market and the launch represents the most significant Mucinex line extension in several years.

Other innovation activity in Q1 2026 included Finish premium format upgrades, Vanish Quick Wash formulation improvements, Dettol’s Activ Botany range activation across European markets, Durex Intensity range upgrades, the Chinese Intima Foam Wash launch, and a high-strength extension to the Mead Johnson specialty portfolio. The launch cadence supports the long-term Powerbrand strategy of innovating into adjacent categories and higher-margin premium segments.

The execution risk is that innovation launches typically take 12 to 24 months to reach full revenue contribution, meaning the H2 2026 acceleration depends partly on the early traction of these June and subsequent launches. If retailer placement, consumer adoption and competitive response play out as expected, the launches should contribute meaningfully to growth. If any of these factors disappoint, the H2 trajectory could fall short of the 4% to 5% full-year target.

What are the execution risks Kris Licht and Shannon Eisenhardt face over the next 12 months?

Kris Licht, chief executive since 2023, has been the architect of the post-Essential Home restructuring strategy. His tenure has been characterised by the strategic focus on Core Reckitt Powerbrands, the disciplined disposal of non-core assets, and the build-out of the Fuel for Growth productivity programme. The challenge over the next 12 months is to convert that strategic clarity into share price performance, with the persistent gap between the consensus 6,229p price target and the current 4,551p share price suggesting that the market is not yet convinced.

The first specific risk is the Mead Johnson sale completion. Until a definitive transaction is announced, the share price will continue to reflect uncertainty about the final value, structure and timing. A clean deal with Danone or another strategic buyer at a strong valuation would remove this overhang and likely trigger a meaningful share price recovery. A complex deal with retained litigation liabilities, or further extended timeline without resolution, would extend the current weakness.

The second risk is the H2 margin recovery. The 200 basis point H1 compression versus H1 2025 needs to reverse comprehensively in H2 for the full-year guidance to be met. This depends on cold and flu season normalisation, pricing landing, productivity savings accelerating, and commodity costs not escalating further. Any combination of these factors disappointing would result in a missed full-year target, triggering further share price downside.

The third risk is the broader strategic question of whether Core Reckitt alone can deliver sustained 4% to 5% like-for-like growth in a more challenging consumer environment. The competitive set including Procter and Gamble, Unilever, Colgate-Palmolive, Kimberly-Clark and Henkel all face similar input cost and consumer demand pressures, but Reckitt’s smaller scale and category concentration may amplify the impact of any individual sub-segment weakness.

Why are retail investors on UK forums increasingly viewing Reckitt as a contrarian value opportunity?

Forum chatter on London South East, ADVFN and Stockopedia has been actively engaged with Reckitt through 2026. The dominant retail investor framing positions Reckitt as a high-quality consumer health franchise temporarily out of favour due to the Mead Johnson overhang, the H1 margin compression and the broader consumer staples sector rotation. The share price decline from above 6,000p in January to below 4,600p in May has created what some forum participants view as one of the most attractive entry points in the FTSE 100 defensive sector.

The bull case being articulated on retail forums points to five pillars. First, the 4.4% dividend yield at current levels provides meaningful income, with the dividend backed by strong free cash flow and limited cover concerns. Second, the £1 billion buyback running through 2026 provides technical support to the share price while reducing the share count at compressed valuations. Third, the Mead Johnson sale resolution is approaching, with each passing month bringing the binary catalyst closer. Fourth, the Core Reckitt 5.2% 2025 growth demonstrates that the underlying business is working. Fifth, the consensus 37% upside to the average price target reflects analyst conviction in the eventual recovery.

The bear case on the same forums focuses on three concerns. First, the prolonged Mead Johnson sale process has already destroyed substantial shareholder value through the persistent overhang, with no clear timeline for resolution. Second, the broader GLP-1 and Make America Healthy Again consumer environment may compress long-term volume growth across the consumer health portfolio. Third, the H1 margin compression of 200 basis points is more severe than expected, raising questions about whether the underlying cost base flexibility is as strong as management has indicated.

Key catalysts and watchpoints for Reckitt shareholders heading into the H1 2026 interim results

• Reckitt shares close up 0.11% at 4,551p on Friday, May 15, 2026, near the 52-week low of 4,518p, with the stock having lost more than 25% from January 2026 levels above 6,000p despite the disciplined restructuring underway under chief executive Kris Licht.
• The Q1 2026 trading update on April 22 delivered Core Reckitt like-for-like net revenue growth of 1.3%, or 3.1% excluding seasonal OTC headwinds, with Emerging Markets up 7.6% to £1,087 million and Europe down 4.2%.
• Full-year guidance is maintained for Core Reckitt like-for-like net revenue growth of 4% to 5%, with H1 2026 Group adjusted operating margin expected approximately 200 basis points below H1 2025’s 24.6% and H2 margin recovery driving the full-year outlook.
• The Mead Johnson Nutrition sale process remains active with Danone reported as the leading strategic buyer interest, though no formal transaction has been announced and US infant formula litigation overhangs the negotiation timeline.
• The Essential Home divestment closed at end-2025 at approximately $5 billion enterprise value, with Reckitt retaining a 30% associate stake and £25 million of transitional services income through 2026.
• The £1 billion share buyback programme has £669 million completed as of April 17, 2026, providing technical support to the share price while reducing share count at compressed valuations.
• The Mucinex 12 Hour Cold and Fever launch in June 2026 in North America is the most significant near-term innovation event, addressing multi-symptom relief demand in the leading US cold and flu category.
• The H1 2026 interim results on July 29, 2026 provide the next major catalyst, where Kris Licht and chief financial officer Shannon Eisenhardt will need to demonstrate that the H2 margin recovery is on track and progress on the Mead Johnson sale process.